Global Biologics Market Forecast to Expand to $200 bn by 2014, Reports FirstWord

26 Sep 2012 • by Natalie Aster

The global market for biologics is forecast to expand from $138 billion in 2010 to $200 billion by 2014, with much of this extraordinary growth being driven by the approval of new high-priced products for the treatment of conditions that become more prevalent with age.

According to the report “Charting the Biosimilar and Biobetter Development Pipeline” by FirstWord, now, with many patents of the best-selling biologics on the market expected to expire within the next five years, there is considerable interest in launching biosimilar or biobetter versions of these products.

Report Details:

Charting the Biosimilar and Biobetter Development Pipeline
Published: September, 2012
Pages: 428
Price: US$ 1.950,00

In common with the immunomodulator mAbs, cytotoxic mAbs have succeeded in generating high global sales as a result of their use in indications with high levels of unmet need and their ability to command high prices. With global sales of $6.6 billion Avastin is an attractive proposition for the developers of biosimilars, although with patent protection in the US to 2019 and in the EU to 2018 launch in these markets is not imminent. By contrast, Herceptin is only protected in the EU until 2012 so there is the potential for biosimilar market entry in 2012, and with global sales of $5.8 billion it is also a compelling product of which to want to make biosimilars. Analysts believe that Celltrion is likely to be the first entrant to the EU market for biosimilar Herceptin with possible filing before the end of 2012.

More information can be found in the report “Charting the Biosimilar and Biobetter Development Pipeline” by FirstWord.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970